MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study
An experimental cancer drug showed manageable safety and clinical activity in heavily pretreated multiple myeloma patients.
BACKGROUND: The optimal treatment strategy for relapsed or refractory multiple myeloma remains unclear. INTERPRETATION: MK-4002 had manageable safety and clinical activity at doses of 2·15 mg or higher in participants with heavily pretreated relapsed or refractory multiple myeloma.
What the study was
- Study design
- Observational/Cohort Study
- Population
- BACKGROUND: The optimal treatment strategy for relapsed or refractory multiple myeloma remains uncle
- Sample size
- 15
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The Lancet. Haematology
Why it surfaced
First-in-human or CAR-T study with outcomes; moderate relevance to watchlist
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.